06/2024
On 24 June, Vaccentis held a cross-functional Advisory Board under the leadership of our Head…
06/2024
The Annual General Meeting of Vaccentis AG took place on 20 June 2024 at the offices of…
05/2024
Take a look at a scientific report on the possibilities for treating renal cell cancer.…
05/2024
Our CEO Martin Munte had the opportunity to speak with the Vienna City Councillor for…
04/2024
At the Swiss Biotech Day 2024 in Basel, our Head of Research and Development Dr.Ingrid Rauter presented the…
02/2024
Ingrid Rauter, Head of Research and Development and Chief Medical Officer, gave a comprehensive overview of…
02/2024
It was a great pleasure to be able to attend the fourth edition ofInvest In…
01/2024
We are very proud to publish our press release on the research and treatment of…
01/2024
Starting 2024 with an outlook on our goals π―π¨βπ©βπ§βπ¦ Further build R&D organization hiring additional internal HR…
01/2024
Just in time for the start of the new year, we bring a press article…
12/2023
Our last translational advisory board of the year dealing with aspects of autologous tumor vaccine production…
12/2023
Please read a very nice article about Vaccentis in oe24.at Krebs "wegimpfen": Wird das dank neuer Forschung…
11/2023
Very interesting summary article on therapeutic cancer vaccines and their mechanisms of action. Principles of…
11/2023
Great portrait of our Head of Research & Development and CMO, Dr. Ingrid Rauter. Ingrid talks…
10/2023
Please read an article on the adjuvant treatment options in Renal Cell Carcinoma. This summary…